Leerink Partnrs Issues Positive Forecast for AxoGen Earnings

AxoGen, Inc. (NASDAQ:AXGN) – Investment analysts at Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for shares of AxoGen in a research note issued to investors on Monday, November 25th. Leerink Partnrs analyst M. Kratky now expects that the medical equipment provider will post earnings per share of ($0.31) for the year, up from their prior estimate of ($0.32). The consensus estimate for AxoGen’s current full-year earnings is ($0.30) per share. Leerink Partnrs also issued estimates for AxoGen’s Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.06) EPS, FY2026 earnings at $0.17 EPS, FY2027 earnings at $0.26 EPS and FY2028 earnings at $0.34 EPS.

AXGN has been the topic of a number of other reports. StockNews.com upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. JMP Securities lifted their price target on AxoGen from $17.00 to $20.00 and gave the company a “market outperform” rating in a research note on Friday, August 9th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $15.00.

AxoGen Price Performance

Shares of NASDAQ:AXGN opened at $13.61 on Wednesday. The company’s 50 day moving average is $13.73 and its two-hundred day moving average is $10.68. AxoGen has a 52 week low of $5.55 and a 52 week high of $15.90. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of AXGN. Quest Partners LLC increased its position in AxoGen by 23,066.7% during the 3rd quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 2,076 shares in the last quarter. nVerses Capital LLC acquired a new position in shares of AxoGen in the third quarter valued at approximately $56,000. Koss Olinger Consulting LLC purchased a new position in shares of AxoGen during the second quarter valued at approximately $75,000. Lazard Asset Management LLC lifted its stake in shares of AxoGen by 30.1% during the first quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock valued at $93,000 after buying an additional 2,671 shares during the period. Finally, Acadian Asset Management LLC acquired a new stake in AxoGen during the second quarter worth approximately $125,000. 80.29% of the stock is owned by hedge funds and other institutional investors.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.